Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (January 2019)
13 slides from Axim Biotechnologies's investor presentation, Jan 15, 2019
Slide 1: Management Presentation January 2019
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT ‘This presentation includes “forwarcHlookingstaterents” within the meshing ofthe safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, These statements arebased upon the current belies and exectations of AXIMs management andl are subjectto signifi
Slide 3: About AXIM Biotech
ABOUT AXIM BIOTECH A AXIM® Biotechnologies, Inc. (AXIM) is a world leacer AXIM BIOTECH in the research and cev of cannabinoid- Changing Lives basec pharmaceutical procuc Along with buileing a rob portfolio, A) _ Mis focusec on clinical development programs that bring more efficacy and/or lower side
Slide 4: Our Flagship Products
OUR FLAGSHIP PRODUCTS Focused clinical development program with 3 flagship products formulated and ready for further research MedChew® with Dronabinol Dronabinol-based gum thal utilizes AXIM’s proprietary chewing gum delivery system aiming to be bioequivalent to an FDA- approved medication treating
Slide 5: Intellectual Property
Intellectual Property * Worldwide patent on cannabinoid-based chewing gum delivery systern * Dither patents include: suppository delivery system, combination opioid antagonist and cannabinoid products, combination anti-bacterial and cannabinoid products, and more * Patented extraction and purificati
Slide 6: Short and Mid-Term Strategic Positioning
SHORT AND MID-TERM STRATES POSTIONNG Focused busines Waxiivethe weof pteted —Sraepgrojrtselecton, hat Uae rtngard addtional Manet eine impli tarsmucoa consoled: tasaMochanceaf being partnership futher rutraceutcal roduc CEQydeserefor pedo eessocheningpumdeliey brouhttomanetorFOC, ——celopmentof produ
Slide 7: Short & Mid-Term Product Pipeline
SHORT & MID-TERM PRODUCT PIPELINE Drug Application Indication Pre-clinical Formulation Bioequivalence Market MedChew w/Dronabinol © ChewingGum — Nausea/Vomiting/Loss of Appetite DD > Drug Application Indication Pre-clinical Phase 1 Phase 2 Phase 3 MedChew RL ChewingGum Restless Leg Syndrome > MedChe
Slide 8: Market Analysis
MARKET ANALYSIS i Global Drug-Related Nausea/Vomiting/Loss of Restless Leg Syndrome Multiple Sclerosis market by sf A Psychosis market in 2016 Appetite (Source Global Market Size (Source) | 2025 from $16.3 Billion in 2017 | °°" ppetite (Source) with CAGR of 6.3% (Source) with future CAGR 2.5% (Sourc
Slide 9: Competitive
COMPETITIVE The average market cap of the 3 leading medical CBN public companies (GWPH, INSY, ZYNE) i ) Pharmaceutical GW insws Zz fastbe Dramacouicals THERAPEUTICS ING The average market cap of the 3 leading consumer CBN public companies (CVSI, ELLXF, USNA) is $ n Nutraceutical €bXiNO!
Slide 10: Prioritizing In-Focus Areas, Reducing Operating Expenses
PRIORITIZING INFOCUS AREAS, REDUCING OPERATING EXPENSES In the short term, AXIM has identified the projects that have the best chance to make it to market within 24-48 months, with remaining initiatives movec to future development phases For current or upcoming Phase | trials, AXIM has selected: 1)
Slide 11: Proven Management Team
PROVEN MANAGEMENT TEAM George Anastassov, MD, DDS, MBA Founder | Chairman of the Board of CanChew es, LLC anc Director Co-founcer, Biotechnole and GP of Sanammac Founcation anc 1ammad Pharmaceuticals, BV. R&D in M Biotechnolog John W. Huemoeller II Chief Executive Officer Over 35 years of experience
Slide 12: World Renowned Advisory Board
WORLD RENOWNED ADVISORY BOARD Renger Witkamp, Pro Chair in Nutrition and Pharmacology at Wageningen University, the best university in the Netherlands and No. 1 worldwice in agriculture and forestry John Zajicek, Profes: Vice Dean Research and Chair of Clinical Neuroscience with the Plymouth Univers
Slide 13: AXIM Biotech
AXIM BIOTECH For further information, please contact: Tel. +1 844 294 6246 info@aximbiotech.com. www.aximbiotech.com North American Address: 45 Rockefeller Plaza, 20th Floor, New York, NY 10111, USA +1 844 294 6246 European Address: Boelewerf 32, Unit 3, 2987 VD Ridderkerk, The Netherlands +31 10 82
AXIM Biotechnologies — Investor Presentation (January 2019) on 6ix